EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)

Hiroko Bando, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori E Nagai, Masaya Hattori, Kenichi Watanabe, Nobuko Tamura, Manabu Futamura, Kei Koizumi, Naoki Niikura, Tempei Miyaji und 4 weitere

Breast Cancer · 2025

DOI: 10.1007/s12282-025-01744-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Breast Cancer, 2025. Verfasst von Hiroko Bando und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast-Thyroid-Endocrine Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. bando@md.tsukuba.ac.jp. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Exercise, Mobile Applications. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To summarize descriptively health-related quality of life (HRQOL) and physical activity (PA) evaluated with a mobile application and wearable device among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) advanced breast cancer (ABC) treated with first- or second-line palbociclib plus endocrine therapy (ET) or ET alone.

Methods

HRQOL was assessed with the EORTC QLQ-C30 at baseline and Day 15 of 6 treatment cycles (~ 24 weeks). PA metrics were averaged on a weekly basis for 24 weeks. Co-primary endpoints were mean change from baseline in Global Health Status (GHS) and sedentary time.

Results

Ninety-nine patients were enrolled; 78 received palbociclib plus ET (mean age: 57.2 years; 75.6% initiated first-line treatment) and 21 received ET alone (mean age: 56.3 years; 90.5% initiated first-line treatment). Baseline mean GHS score was 60.9 in the palbociclib plus ET group and 64.3 in the ET alone group; mean changes from baseline to Day 15 of Cycle 6 were +4.8 and +2.9, respectively, and not deteriorated beyond the 10-point clinically significant threshold in either treatment group. Baseline mean sedentary time was 581 min/day in the palbociclib plus ET group and 513 min/day in the ET alone group; mean changes from baseline to Week 24 were −22 and −102 min/day, respectively.

Conclusions

In this real-world study of women with HR+/HER2− ABC in Japan, neither palbociclib plus ET nor ET alone had any substantial detrimental impacts on HRQOL, according to patients’ assessments recorded in a smartphone-based mobile application, and PA, as measured by a wearable device.

Trial registration

ClinicalTrials.gov NCT04736576; registered, February 3, 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsExerciseMobile ApplicationsPiperazinesQuality of LifeWearable Electronic DevicesAdultAgedFemaleHumansMiddle AgedAntineoplastic Agents, HormonalLongitudinal StudiesPyridinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Stichwörter der Autor:innen

Advanced breast cancerEndocrine therapyHR +/HER2 −Health-related quality of lifePalbociclibPhysical activity

Substanzen

Antineoplastic Agents, HormonalPiperazinesPyridinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanpalbociclib

Autor:innen und Institutionen

  • Department of Breast-Thyroid-Endocrine Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. bando@md.tsukuba.ac.jp.
  • Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, Japan.
  • Department of Breast and Endocrine Surgery, Akita University Hospital, Akita, Japan.
  • Department of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
  • Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.

Förderung

  • Pfizer Inc.

Zitieren

APA

Bando, H., Ueda, A., Terata, K., Doi, M., Nagai, S. E., Hattori, M., Watanabe, K., Tamura, N., Futamura, M., Koizumi, K., Niikura, N., Miyaji, T., Muramatsu, Y., Xu, L., Masuda, N., & Saji, S. (2025). Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26). Breast Cancer. https://doi.org/10.1007/s12282-025-01744-0

Vancouver

Bando H, Ueda A, Terata K, Doi M, Nagai SE, Hattori M, et al. Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26). Breast Cancer. 2025. doi:10.1007/s12282-025-01744-0

BibTeX
@article{Bando2025,
  author = {Bando, Hiroko and Ueda, Aya and Terata, Kaori and Doi, Mihoko and Nagai, Shigenori E and Hattori, Masaya and Watanabe, Kenichi and Tamura, Nobuko and Futamura, Manabu and Koizumi, Kei and Niikura, Naoki and Miyaji, Tempei and Muramatsu, Yasuaki and Xu, Linghua and Masuda, Norikazu and Saji, Shigehira},
  title = {Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-025-01744-0}
}
Kostenlos starten →